SWM
TVRD

SeaCrest Wealth Management’s Tvardi Therapeutics TVRD Stock Holding History

SeaCrest Wealth Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-46
Closed -$33K – 1903
2019
Q1 		$33K Sell
46
-5
-10% -$2.99K 0.01% 1086
2018
Q4 		$24K Hold
51
– – ﹤0.01% 1184
2018
Q3 		$44K Buy
51
+14
+38% +$10.1K 0.01% 1061
2018
Q2 		$25K Sell
37
-8
-18% -$4.07K ﹤0.01% 1278
2018
Q1 		$20K Sell
45
-17
-27% -$8.25K ﹤0.01% 1339
2017
Q4 		$27K Buy
+62
New +$28.3K ﹤0.01% 1219

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

SeaCrest Wealth Management's TVRD Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Tvardi Therapeutics (TVRD) in Q2 2019, closing a stake of 46 shares — an estimated $33K sold.

SeaCrest Wealth Management first reported a position in TVRD in Q4 2017 and held it in 6 quarters. The position peaked at $44K in Q3 2018. 126 funds tracked by Wall St. Rank hold TVRD as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining Tvardi Therapeutics position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 46 Tvardi Therapeutics shares in Q2 2019, an estimated $33K.
  • SeaCrest Wealth Management first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 6 quarters.
  • SeaCrest Wealth Management's Tvardi Therapeutics position peaked at $44K in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.